16-04-2025
April 2025 European Penny Stocks With Promising Potential
Amid escalating trade tensions and the lowest consumer sentiment in nearly three years, European markets have experienced notable volatility. Despite these challenges, the concept of penny stocks remains relevant as investors seek affordable opportunities with growth potential. Typically associated with smaller or newer companies, these stocks can offer significant upside when backed by strong financials and solid fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
Bredband2 i Skandinavien (OM:BRE2)
SEK2.08
SEK1.99B
★★★★☆☆
Transferator (NGM:TRAN A)
SEK2.64
SEK238.86M
★★★★★☆
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Hifab Group (OM:HIFA B)
SEK3.88
SEK236.05M
★★★★★★
IMS (WSE:IMS)
PLN3.55
PLN120.32M
★★★★☆☆
FAE Technology (BIT:FAE)
€2.34
€46.86M
★★★★☆☆
Cellularline (BIT:CELL)
€2.51
€52.94M
★★★★★☆
Netgem (ENXTPA:ALNTG)
€0.98
€32.82M
★★★★★★
Arcure (ENXTPA:ALCUR)
€4.10
€23.74M
★★★★☆☆
Deceuninck (ENXTBR:DECB)
€2.14
€295.46M
★★★★★★
Click here to see the full list of 425 stocks from our European Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: High Co. SA offers consumer engagement chain solutions in France, Belgium, and Spain with a market cap of €60.12 million.
Operations: The company generates its revenue from advertising, amounting to €146.38 million.
Market Cap: €60.12M
High Co. SA, with a market cap of €60.12 million, operates in France, Belgium, and Spain offering consumer engagement solutions. Despite trading at 67% below its estimated fair value and having more cash than debt, the company faces challenges such as declining earnings forecasts over the next three years and negative earnings growth of -27.4% last year. Its net profit margins have decreased from 7.3% to 5.3%. However, recent announcements include a dividend increase to €0.25 per share for fiscal year 2024 and an exceptional dividend of €1 per share due to asset disposal income.
Navigate through the intricacies of High with our comprehensive balance sheet health report here.
Learn about High's future growth trajectory here.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: MEMSCAP, S.A. offers micro-electro-mechanical systems (MEMS) based solutions across aerospace and defense, optical communications, medical, and biomedical sectors globally with a market cap of €30.70 million.
Operations: The company's revenue is primarily derived from the aerospace segment at €8.20 million, followed by the medical sector at €3.15 million, and optical communications contributing €1.24 million.
Market Cap: €30.7M
MEMSCAP, S.A., with a market cap of €30.70 million, shows financial resilience despite recent challenges. The company has ample short-term assets (€11.9M) to cover both short and long-term liabilities (€3.2M and €4.3M respectively), while its debt is well covered by operating cash flow (2107.7%). However, earnings have declined over the past year (-35.8%), impacting net profit margins which fell from 15.2% to 10.9%. The company's share price remains highly volatile, and it recently delisted from OTC Equity due to inactivity but completed a share buyback of 1.34% for €0.48 million in late 2024.
Get an in-depth perspective on MEMSCAP's performance by reading our balance sheet health report here.
Review our growth performance report to gain insights into MEMSCAP's future.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Medivir AB (publ) is a pharmaceutical company that develops and commercializes cancer treatments in the Nordic region, Europe, and internationally, with a market cap of SEK207.51 million.
Operations: The company's revenue is entirely derived from its Pharmaceuticals segment, amounting to SEK3.5 million.
Market Cap: SEK207.51M
Medivir AB, with a market cap of SEK207.51 million, operates in the pharmaceutical sector focusing on cancer treatments. Despite being pre-revenue with sales of just SEK3.5 million and facing a net loss of SEK123.3 million in 2024, Medivir's recent patent grant for fostroxacitabine bralpamide combined with Lenvima offers significant potential market exclusivity until 2041. The company presented promising final data from its phase 1b/2a study at the EASL Summit, showing improved outcomes in advanced liver cancer treatment. Though unprofitable and volatile, Medivir remains debt-free and has short-term assets exceeding liabilities but faces cash runway challenges under current conditions.
Click to explore a detailed breakdown of our findings in Medivir's financial health report.
Examine Medivir's earnings growth report to understand how analysts expect it to perform.
Jump into our full catalog of 425 European Penny Stocks here.
Searching for a Fresh Perspective? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTPA:HCO ENXTPA:MEMS and OM:MVIR.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
